Every 10-Q that Evofem Bioscienc (EVFM) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow EVFM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EVFM filings page.
Evofem Biosciences reported Q2 2026 net product sales of $2.6 million, down from $4.8 million a year earlier, and a net loss of $11.0 million, widening from $1.8 million. For the first six months of 2026, net product sales were $3.5 million with a net loss of $16.5 million.
Total assets were $7.5 million at June 30, 2026, versus total liabilities of $90.0 million, and stockholders’ deficit of $87.5 million. The company reported a working capital deficit of $82.5 million and an accumulated deficit of $914.0 million, and stated that these conditions raise substantial doubt about its ability to continue as a going concern.
Evofem continues commercializing PHEXX and, since July 2024, SOLOSEC, and has added ex-U.S. distribution agreements in the Middle East, North Africa, and sub-Saharan Africa. However, it remains highly leveraged, with significant convertible notes and senior subordinated notes and ongoing default disputes on the Baker notes.
Evofem Biosciences reports first-quarter 2026 results showing a small commercial base and significant financial strain. Product sales, net, were $0.9 million, up slightly from $0.8 million a year earlier, while total operating expenses were $5.5 million, leading to an operating loss of $4.6 million and a net loss of $5.5 million attributable to common stockholders, or $(0.04) per share.
Cash, cash equivalents and restricted cash totaled $2.4 million as of March 31, 2026, versus current liabilities of $78.8 million, leaving a working capital deficit of about $72.7 million and a stockholders’ deficit of $77.6 million. Management states that these conditions and dependence on new financing raise substantial doubt about the company’s ability to continue as a going concern.
The company continues commercial activities for non-hormonal contraceptive gel PHEXX and antimicrobial SOLOSEC, expanding through ex-U.S. licensing and distribution agreements in the Middle East, North Africa and sub-Saharan Africa. However, large outstanding convertible and senior notes and extensive potential dilution underscore that the capital structure remains highly leveraged and complex.
Evofem Biosciences (EVFM) filed its Q3 2025 10‑Q, showing modest revenue and ongoing financial pressure. Net product sales were $4.952 million for the quarter and $10.622 million year‑to‑date. Q3 operating income was $0.951 million, aided by a $1.933 million gain from a change in accounting estimates on a contingent royalty liability, but other expenses led to a net loss of $1.569 million for Q3 and $2.397 million for the first nine months.
Liquidity remains tight: cash, cash equivalents and restricted cash were $840 thousand at period end. Total assets were $13.807 million versus total liabilities of $83.976 million, resulting in a stockholders’ deficit of $75.066 million. Management disclosed substantial doubt about the company’s ability to continue as a going concern and outlined plans to pursue product revenues, milestones from ex‑U.S. licensing, restructuring of payables, and additional financing. The company’s common stock moved from OTCQB to OTCPK on April 23, 2025, and to OTCID on July 1, 2025. Common shares outstanding were 123,956,354 as of September 30, 2025, and 126,685,925 as of November 12, 2025.